Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.
Gallois C, Emile JF, Kim S, Monterymard C, Gilabert M, Bez J, Lièvre A, Dahan L, Laurent-Puig P, Mineur L, Coriat R, Legoux JL, Hautefeuille V, Phelip JM, Lecomte T, Sokol H, Capron C, Randrian V, Lepage C, Lomenie N, Kurtz C, Taieb J, Tougeron D. Gallois C, et al. Among authors: sokol h. Dig Liver Dis. 2021 Oct;53(10):1254-1259. doi: 10.1016/j.dld.2021.06.009. Epub 2021 Jun 30. Dig Liver Dis. 2021. PMID: 34215534 Free article.
Air mass pushing the liver.
Barret M, Coriat R, Beaugerie L, Sokol H. Barret M, et al. Among authors: sokol h. Dig Liver Dis. 2011 Dec;43(12):1025. doi: 10.1016/j.dld.2011.06.005. Epub 2011 Jul 12. Dig Liver Dis. 2011. PMID: 21752737 No abstract available.
[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R, Pudlarz T, Garcia-Larnicol ML, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T. Cohen R, et al. Among authors: sokol h. Bull Cancer. 2020 Apr;107(4):438-446. doi: 10.1016/j.bulcan.2019.11.016. Epub 2020 Feb 10. Bull Cancer. 2020. PMID: 32057467 Free article. French.
Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group.
Nachury M, Bouhnik Y, Serrero M, Filippi J, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N, Peyrin-Biroulet L, Gilletta C, Tadbiri S, Allez M, Viennot S, Bourreille A, Laharie D, Amiot A; GETAID-patient experience study group. Nachury M, et al. Dig Liver Dis. 2021 Apr;53(4):434-441. doi: 10.1016/j.dld.2020.10.020. Epub 2020 Nov 10. Dig Liver Dis. 2021. PMID: 33187920 Free article.
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.
Evrard C, Louvet C, Hajbi FE, Fiore FD, Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F, Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanan A, Sokol H, Chibaudel B, Desrame J, Pierre S, Gonzalez D, Lepage C, Tougeron D. Evrard C, et al. Among authors: sokol h. Dig Liver Dis. 2021 Apr;53(4):420-426. doi: 10.1016/j.dld.2020.11.036. Epub 2021 Jan 6. Dig Liver Dis. 2021. PMID: 33358124 Free article. Clinical Trial.
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID.
Amiot A, Seksik P, Reimund JM, Nachury M, Altwegg R, Bourreille A, Viennot S, Fumery M, Roblin X, Serrero M, Allez M, Painchart C, Chanteloup E, Vuitton L, Fotsing G, Buisson A, Coulibaly B, Nancey S, Gilletta C, Plastaras L, Abitbol V, Guillo L, Simon M, Nahon S, Laharie D, Peyrin-Biroulet L, Bouguen G; anti-TNF contraindication study group. Amiot A, et al. Dig Liver Dis. 2022 Oct;54(10):1350-1357. doi: 10.1016/j.dld.2022.04.011. Epub 2022 May 14. Dig Liver Dis. 2022. PMID: 35577685 Free article.
FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer.
Randrian V, Pernot S, Le Malicot K, Catena V, Baumgaertner I, Tacher V, Forestier J, Hautefeuille V, Tabouret-Viaud C, Gagnaire A, Mitry E, Guiu B, Aparicio T, Smith D, Dhomps A, Tasu JP, Perdrisot R, Edeline J, Capron C, Cheze-Le Rest C, Emile JF, Laurent-Puig P, Bejan-Angoulvant T, Sokol H, Lepage C, Taieb J, Tougeron D. Randrian V, et al. Among authors: sokol h. Dig Liver Dis. 2022 Jul;54(7):857-863. doi: 10.1016/j.dld.2022.04.024. Epub 2022 May 21. Dig Liver Dis. 2022. PMID: 35610167 Free article. Clinical Trial.
Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study.
Guillo L, Flachaire B, Avouac J, Dong C, Nachury M, Bouguen G, Buisson A, Caillo L, Fumery M, Gilletta C, Hébuterne X, Lafforgue P, Laharie D, Mahé E, Marotte H, Nancey S, Ottaviani S, Salmon JH, Savoye G, Serrero M, Uzzan M, Viguier M, Richez C, Peyrin-Biroulet L, Seksik P, Pham T; COMBIO Study Group. Guillo L, et al. Dig Liver Dis. 2023 Jan;55(1):61-68. doi: 10.1016/j.dld.2022.07.012. Epub 2022 Aug 16. Dig Liver Dis. 2023. PMID: 35985961
432 results